125 Participants Needed

Mirvetuximab Soravtansine + Carboplatin for Ovarian Cancer

Recruiting at 71 trial locations
II
MM
HS
Overseen ByHye Sook Chon
Age: 18+
Sex: Female
Trial Phase: Phase 2
Sponsor: AbbVie
Must be taking: Platinum-based chemotherapy
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy.

Do I need to stop my current medications to join the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, you must have stabilized or recovered from all prior therapy-related side effects and have discontinued any maintenance therapy at least 4 weeks before starting the trial treatment.

What data supports the effectiveness of the drug Mirvetuximab Soravtansine combined with Carboplatin for ovarian cancer?

Mirvetuximab Soravtansine has shown promising results in treating ovarian cancer, particularly in patients with platinum-resistant disease, with a 32.4% response rate and a median response duration of 6.9 months. Additionally, when combined with another drug, bevacizumab, it demonstrated a 64% response rate, indicating its potential effectiveness in combination therapies.12345

Is the combination of Mirvetuximab Soravtansine and Carboplatin safe for humans?

The combination of Mirvetuximab Soravtansine and Carboplatin has been studied for safety in ovarian cancer patients. Mirvetuximab Soravtansine can cause low-grade eye and stomach-related side effects, which are generally manageable. Corticosteroid eye drops have been used to help manage eye-related side effects.12367

What makes the drug Mirvetuximab Soravtansine + Carboplatin unique for treating ovarian cancer?

This drug combination is unique because Mirvetuximab Soravtansine is an antibody-drug conjugate that specifically targets the folate receptor alpha, which is often present in ovarian cancer cells, allowing for targeted delivery of the chemotherapy agent DM4. This targeted approach aims to improve effectiveness and reduce side effects compared to traditional chemotherapy.12368

Research Team

AI

ABBVIE INC.

Principal Investigator

AbbVie

Eligibility Criteria

This trial is for adults with high-grade ovarian, primary peritoneal, or fallopian tube cancer that's sensitive to platinum-based chemo and has returned after one treatment round. Participants must have a certain level of tumor cell positivity for FRα, be in good physical condition (ECOG 0-1), and not pregnant. They can't join if they've had more than one chemo round, severe eye conditions, prior MIRV treatments, certain other cancers within the last three years or serious health issues.

Inclusion Criteria

Females of childbearing potential (FCBP) must agree to use highly effective contraceptive method(s) while on study medication and for at least 3 months after the last dose of MIRV and 6 months after the last dose of carboplatin
My blood, liver, and kidney functions are all within normal ranges.
I have had treatment with a PARPi due to my BRCA-positive status.
See 13 more

Exclusion Criteria

You need to take supplements that contain folate.
I have a serious heart condition.
I have ongoing eye problems that need regular treatment or monitoring.
See 15 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive carboplatin plus mirvetuximab soravtansine for 6 cycles, followed by continuation with mirvetuximab soravtansine alone

18 weeks
6 visits (in-person, every 3 weeks)

Continuation

Participants continue with single-agent mirvetuximab soravtansine if they have stable disease, complete response, or partial response

Up to 3 years
Every 3 weeks (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 3 years

Treatment Details

Interventions

  • Carboplatin
  • Mirvetuximab soravtansine
Trial Overview The study tests carboplatin combined with mirvetuximab soravtansine followed by just mirvetuximab soravtansine in patients whose tumors express folate receptor-alpha (FRα) and are recurrent but respond to platinum drugs. It's an open-label phase 2 trial where all participants receive the experimental therapy.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: MIRV + CarboplatinExperimental Treatment2 Interventions
On Day 1 of every 3-week cycle (Q3W) for 6 cycles, MIRV will be given at the dosage of 6 mg/kg of AIBW along with carboplatin given at area under the AUC5 administered through intravenous (IV) infusion (maximum dosing per National Comprehensive Cancer Network \[NCCN\] guidelines \[NCCN 2021\]). Upon completion of carboplatin plus MIRV treatment, single-agent MIRV will be continued at the tolerated dose on Day 1 Q3W in participants with investigator determined stable disease (SD), complete response (CR) or partial response (PR).

Carboplatin is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Paraplatin for:
  • Ovarian cancer
  • Testicular cancer
  • Lung cancer
  • Head and neck cancer
  • Brain cancer
🇪🇺
Approved in European Union as Carboplatin for:
  • Ovarian cancer
  • Small cell lung cancer
🇨🇦
Approved in Canada as Carboplatin for:
  • Ovarian cancer
  • Small cell lung cancer
  • Testicular cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

AbbVie

Lead Sponsor

Trials
1,079
Recruited
535,000+
Founded
2013
Headquarters
North Chicago, USA
Known For
Immunology treatments
Top Products
Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)

Dr. Roopal Thakkar

AbbVie

Chief Medical Officer since 2023

MD from Wayne State University School of Medicine

Robert A. Michael profile image

Robert A. Michael

AbbVie

Chief Executive Officer

Bachelor's degree in Finance from the University of Illinois

ImmunoGen, Inc.

Lead Sponsor

Trials
33
Recruited
4,000+

Findings from Research

In a study involving 18 patients with recurrent ovarian cancer, the combination of mirvetuximab soravtansine and carboplatin showed a high objective response rate of 71%, indicating significant antitumor activity.
The treatment was generally well-tolerated, with most adverse events being mild, suggesting a favorable safety profile for this combination therapy in patients with platinum-sensitive ovarian cancer.
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.Moore, KN., O'Malley, DM., Vergote, I., et al.[2019]
Mirvetuximab soravtansine is an antibody-drug conjugate that received FDA accelerated approval for treating recurrent platinum-resistant high-grade serous ovarian cancer (HGSOC), showing an overall response rate of 32.4% and a median duration of response of 6.9 months in the SORAYA trial.
The treatment has a favorable safety profile, with primarily low-grade ocular and gastrointestinal toxicities, making it a promising option for patients with high FRα expression in their tumors.
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer.Porter, RL., Matulonis, UA.[2023]
Mirvetuximab soravtansine, an antibody-drug conjugate targeting the folate receptor alpha, has shown promising clinical activity in treating platinum-resistant ovarian cancer, which is known for poor outcomes with standard chemotherapy.
This treatment combines a targeted approach with the cytotoxic effects of a chemotherapy agent, potentially offering a new strategy to overcome drug resistance in ovarian cancer patients.
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.Gonzalez-Ochoa, E., Veneziani, AC., Oza, AM.[2023]

References

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. [2019]
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer. [2023]
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer. [2023]
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. [2019]
Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer. [2021]
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite. [2023]
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. [2020]
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security